Industry4 days ago 4 min read
FDA updates compounding rules for GLP-1 class drugs
New guidance narrows what compounders can produce and how they must label it.
by Editorial team
The update
The FDA issued updated guidance this week affecting compounding pharmacies that produce GLP-1 receptor agonists.
The rules tighten labeling, sourcing, and what may be added to a compounded formulation.
What changes
Compounders may no longer add vitamins, lipotropic agents, or other adjuncts to GLP-1 formulations.
Sourcing must be limited to FDA-registered active pharmaceutical ingredient (API) facilities.
What it means for patients
Some clinics that relied on multi-ingredient blends will need to reformulate or discontinue them.
Patients should expect updated labeling and possibly different products from their current source.